ArticleScientific reports2026
SARS-CoV-2 seroprevalence in Barcelona and Catalonia (Spain) after the 2020 lockdown.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
The study aimed to assess seroprevalence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Barcelona city (SRCOV2-BCN study) and the region of Catalonia, Spain (SRCOV2-CAT study) prior to the availability of coronavirus (COVID-19) vaccines. Humoral response to SARS-CoV-2 infection was assessed by detection of total antibodies (IgG, IgA and IgM) in surplus specimens from routine blood draw in the biochemistry laboratories of the participant hospitals. In Barcelona city, SARS-CoV-2 seroprevalence was 10.2% both in April and July 2020, without differences between men and women. The highest seroprevalence was found in individuals between 50 and 64 years old (13.7%). In Catalonia, SARS-CoV-2 seroprevalence in July 2020 was 9.2% and it was higher in women (10.1%) than in men (7.5%) (P = 0.0066), especially in the 50-64 age group (12.7% in women vs. 5.4% in men, P = 0.00051). The highest prevalence by age groups was 10%, found in individuals between 35 and 64 years old. Seroprevalence in the Barcelona province (11.7%) was higher than in the other provinces. In conclusion, SAR-CoV-2 seroprevalence in Catalonia during the first months of COVID pandemics was moderately high. There were differences by age, sex and geographical location that should be investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.